Insight into recent reforms and initiatives in Austria: Implications for key stakeholders

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 4, 2008, Pages 357-371

  Godman, Brian ^a,b,c   Bucsics, Anna ^b   Burkhardt, Thomas ^b   Haycox, Alan ^c   Seyfried, Hans ^b   Weininger, Peter ^b  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b Hauptverband der Österreichischen Sozialversicherungsträger ^*  (Italy)

^c UNIVERSITY OF LIVERPOOL MANAGEMENT SCHOOL   (United Kingdom)

Author keywords

Austria; Generic; Pharmaceutical; Pharmacoeconomics; Pricing; Reform

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BEVACIZUMAB; BORTEZOMIB; CETUXIMAB; CORTICOSTEROID; DOCETAXEL; ERLOTINIB; ERYTHROPOIETIN; ETANERCEPT; GABAPENTIN; GENERIC DRUG; HISTAMINE H2 RECEPTOR ANTAGONIST; INSULIN; INTERFERON BETA SERINE; METFORMIN PLUS PIOGLITAZONE; METFORMIN PLUS ROSIGLITAZONE; METHOTREXATE; MITOTANE; PEMETREXED; PIOGLITAZONE; PREGABALIN; PROTON PUMP INHIBITOR; RITUXIMAB; ROSIGLITAZONE; SEROTONIN UPTAKE INHIBITOR; SORAFENIB; SULFONYLUREA DERIVATIVE; SUNITINIB; TRASTUZUMAB; UNINDEXED DRUG;

ADRENAL CORTEX CARCINOMA; ADVANCED CANCER; AMBULATORY CARE; AUSTRIA; CANCER SURVIVAL; CHRONIC DISEASE; COST BENEFIT ANALYSIS; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEMYELINATING DISEASE; DEPRESSION; DISEASE FREE SURVIVAL; DRUG CONTRAINDICATION; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG LABELING; DRUG MARKETING; DRUG RESEARCH; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; ECONOMIC DEVELOPMENT; ECONOMIC EVALUATION; EUROPE; EUROPEAN UNION; EVIDENCE BASED MEDICINE; FINANCIAL MANAGEMENT; GOVERNMENT REGULATION; HEALTH CARE COST; HEALTH CARE NEED; HEALTH INSURANCE; HOSPITAL CARE; HOSPITAL PATIENT; HUMAN; HYPERTENSION; INFLAMMATORY DISEASE; KIDNEY CARCINOMA; LUNG CANCER; MEDICAL DECISION MAKING; MEDICAL PRACTICE; MONOTHERAPY; NEUROPATHIC PAIN; NON INSULIN DEPENDENT DIABETES MELLITUS; OVERALL SURVIVAL; PATENT; PHARMACEUTICAL CARE; PRESCRIPTION; PREVALENCE; REIMBURSEMENT; REVIEW; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; STANDARDIZATION;

EID: 55249087050     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.4.357     Document Type: Review

References (36)

1. Hofmarcher M, Rack H-M. Austria: health system review. Health Syst. Trans. 8(3), 1-247 (2006).
2. Sturm H, Austvoll-Dahlgren A, Aaserud M et al. Pharmaceutical policies: effects of financial incentives for prescribers (review). Cochrane Database Syst. Rev. 3, CD006731 (2007).
3. Bero LA, Grilli R, Grimshaw JM et al. Closing the gap between research and practice: an overview of systematic reviews of interventions to promote the implementation of research findings. Br. Med. J. 317, 465-468 (1988).
4. Barber N, Bradley C, Barry C et al. Measuring the appropriateness of prescribing in primary care: are current measures complete? J. Clin. Pharm. Ther. 30, 533-539 (2005).
5. Führlinger S. Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria. Wien. Med. Wochenschr. 156, 612-618 (2006).
6. Barry M, Tilson L. Recent developments in pricing and reimbursement of medicines in Ireland. Expert Rev. Pharmacoeconomics Outcome Res. 7(6), 605-611 (2007).
7. Walter E, Zehetmayr S. Guidelines for health-economic evaluations in Austria. Wien. Med. Wochenschr. 156, 628-632 (2006).
8. Grandfils N, Sermet C. Pharmaceutical policy in France: a mosaic of reforms. Eurohealth 12(3), 15-17 (2006).
9. Allenet B, Barry H. Opinion and behaviour of pharmacists towards the substitution of brand products by generic drugs: survey of 1000 French community pharmacists. Pharm. World Sci. 25(5), 197-202 (2003).
10. Andersson K, Sonesson C, Petzold M et al. What are the obstacles to generic substitution? An assessment of the behaviour of prescribers, patients and pharmacies during the first year of generic substitution in Sweden. Pharmacoepidemiol Drug Saf. 14, 341-348 (2005).
11. Godman B, Haycox A, Schwabe U, Joppi R, Garattini S. Having your cake and eating it: office of fair trading proposal for funding riew drugs to benefit patients and innovative companies. Pharmacoeconomics 26(2), 91-98 (2008).
12. Hauptverband der Österreichischen Sozialversicherungsträger. Erstattungskodex - EKO. Gültig ab 1. Jänner 2007.
13. Auterith A. Initiative Arznei & Vernunft-Evaluierung der Therapieempfehlung "Asthma/COPD". Juni 2002 Institut für Medizinische Statistik (alexandra.auterithυnivie.ac.at).
14. Wettermark B, Hammar N, Fored M et al. The news Swedish Prescribed Drug Register - opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol Drug Saf. 16, 726-735 (2007).
15. Wolzt M, Ohrenberger G, Reichardt B. Cost reduction with project based prescription of generic ACE inhibitors. Wien. Klin. Wochenschr. 115 (1-2), 23-28 (2003).
16. Gouya G, Reichardt B, Bidner A, Weissenfels R, Wolzt M. Partial reimbursement of prescription charges for generic drugs reduces costs for both health insurances and patients. Wien. Klin. Wochenschr. 120, 89-95 (2008).
17. Atella V, Schafheutle E, Noyce P, Hassell K. Affordability of medicines and patients cost-reducing behaviour - empirical evidence based on SUR estimates from Italy and UK. Appl. Health Econ. Health Policy 4(1), 23-35 (2005).
18. Jack A. Balancing Big Pharma's books. Br. Med. J. 336, 418-419 (2008).
19. Wettermark B, Godman B, Andersson K, Gustafsson L, Haycox A, Bertele V. Recent national and regional drug reforms in Sweden - unplications for pharmaceutical companies in Europe. Pharmacoeconomics 26(27), 537-550 (2008).
20. Garattini L, Ghislandi S. Off-patent drug in Italy: a short sighted view? Eur. J. Health Econ. 7, 79-83 (2006).
21. Paris V. Pharmaceutical regulation in France 1980 - 2003. Int. J. Health Plann. Manage. 20, 307-328 (2005).
22. Garattini L, Cornago D, De Compadri F. pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 82, 330-339 (2007).
23. Wells J, Cheong-Leen C. NICE appraisal should be everyones business. Br. Med. J. 334, 936-938 (2007).
24. Barrett A, Roques T, Small M, Smith R. How much will herceptin really cost? Br. Med. J. 333, 1118-1120 (2006).
25. Motola D, De Ponti F, Rossi D, Martini N, Montanaro, N. Therapeutic innovation in the EU: analysis of the drugs approved by the EMEA between 1995 and 2003. Br. J. Clin. Pharmacol. 59, 475-478 (2004).
26. Motola D, De Ponti F, Poluzzi E et al. An update on the first decade of the European centralized procedure: how many innovative drugs? Br. J. Clin. Pharmacol. 62, 610-616 (2006).
27. Garattini S, Bertele V. How can we regulate medicines better. Br. Med. J. 335, 803-805 (2007).
28. Kastelein J, Akdim F, Stroes E, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N. Engl. J. Med. 358, 1431-1443 (2008).
29. Lapostolle F, Catineau J, Lapandry C, Adnet F. Endpoints in Studies on myocardial infarction. Lancet 369, 1430 (2007).
30. Melander H, Ahlqvist-Rastad J, Meijer G, Beermann B. Evidence b(i)ased medicine selective reporting from Studies sponsored by pharmaceutical industry: review of studies in new drug applications. Br. Med. J. 326, 1171-1173 (2003).
31. Kirsch I, Deacon BJ, Huedo-Medina TB, Scoboria A, Moore TJ, Johnson B. Initial severity and antidepressant benefits: a meta analysis of data submitted to the Food and Drug Administration. PLoS Med. 5(2), E45 (2007).
32. Duerden M, Miller J, Godman B, Mallinson M, Sullivan N. Centralised guidance - how NICE and SIGN impact on care in the UK. Bausteine fur ein neues Gesundheitswesen - Technik, Ethik, "Okonomie" Kluseri N, Straub E (Eds.). Nomos Verlagsgesellschaft, Baden-Baden (No. 6 of the series " Beitrage zum Gesundheitsmanagement" by Nobert Klusen and Andreas Meusch) (2003).
33. Schneider A, Wensing M, Biessecker K et al. Impact of quality circles for improvement of asthma care: results of a randomized controlled trial. J. Eval. Clin. Pract. 14, 185-190 (2008).
34. Rochaix L, Wilsford D. State autonomy, policy paralysis: paradoxes of institutions and culture in the French health care System. J. Health Polit. Policy Law 30(1-2), 97-119 (2005).
35. Krammer H. Pharmacoeconomic analyses chance or 4th hurdle for innovative drugs. Wien. Med. Wochenschr. 156, 606-611 (2006).
36. IMAS International. Initiative Arznei & Vernunft - Ergebnisse einer repräsentative Resonanzstudie under Ärzten. June 2003. Archiv-Nr.:7074.